DQS: The New Evolution of dd-cfDNA Testing and Noninvasive Rejection Monitoring, Presented by Natera
Release Date: 06/26/2025
DQS: The New Evolution of dd-cfDNA Testing and Noninvasive Rejection Monitoring, Presented by Natera
ISHLT Voices
In this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear transplant cardiologists explore the evolving landscape of post-heart transplant care, zeroing in on the transformative shift from traditional, invasive biopsies to cutting-edge noninvasive molecular diagnostics—particularly cell-free DNA technologies. Brent Lampert, DO Medical Director, Transplant Cardiologist The Ohio State University Wexner Medical Center Columbus, OH USA Ajith P. Nair, MD, FACC, FAHA Associate Professor, Medicine—Cardiology Texas Heart Institute at Baylor College of...
info_outline
Explore Noninvasive Rejection Monitoring in Single Lung Transplantation; A SLAM Study Overview Presented by Natera
ISHLT Voices
In this episode of the ISHLT Voices podcast, hosted by , you’ll hear a discussion on the need for noninvasive surveillance options for single lung transplantation and the role that the Prospera Lung donor derived cell free DNA (dd-cfDNA) test can play. There are inherent, increased risks and challenges associated with management of single lung transplantation over double lung. Monitoring through invasive transbronchial biopsy procedures (TBBx) is often not the best option for these high-risk, frail patients. In this podcast, notable transplant pulmonologists Drs. Rosenheck and Arunachalam...
info_outline
Unlocking Hyperimmunes: Emerging Clinical Data about Cytogam, From Kamada
ISHLT Voices
Presented by Kamada In this episode of the ISHLT Voices podcast, hosted by , you’ll hear a discussion on the utilization of Cytomegalovirus Immune Globulin (CMV IgG) in solid organ transplantation (SOT). First, a focused overview of CMV IgG, including what they are, how they are made, and their role in SOT. The experts describe the differences between hyperimmune globulins like CMV IgG and standard immune globulins (IVIG). Then, enjoy a discussion from the experts on two recently presented poster highlighting CMV IgG use in lung transplantation and the need for new emerging data. SPEAKERS: ...
info_outline
Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
ISHLT Voices
Presented by Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does. In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk...
info_outline
Experts Tackle Bronchiolitis Obliterans Syndrome Part Three, From Zambon USA
ISHLT Voices
Presented by Zambon USA ISHLT Voices returns with another podcast presented by exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part three of this series, experts take a deep dive into CLAD phenotype differentiation, current gaps in diagnosis and management of BOS, emerging treatment strategies, and lastly, discuss the advances made in BOS diagnosis and management over the last decade. Steven Hays, MD Medical Director, Advanced Lung Disease and Lung Transplant Programs University of California, San...
info_outline
Exploratory Evidence Supports Use of Donor-Derived Cell-Free DNA to Monitor Pediatric Heart Transplant Recipients, From Natera
ISHLT Voices
Presented by Natera In this episode of the ISHLT Voices podcast, Dr. Shri Deshpande, a cardiologist at the National Children’s Hospital in Washington, DC USA, discusses his work on improving the care of pediatric heart transplant patients. Dr. Deshpande's research focuses on the use of cell-free DNA in monitoring transplant recipients for rejection. He explains that cell-free DNA, released when cells break down, can be detected in the bloodstream and used as a non-invasive screening tool to assess the health of transplanted organs. The discussion covers the external...
info_outline
Experts Tackle Bronchiolitis Obliterans Syndrome Part Two, From Zambon USA
ISHLT Voices
Presented by Zambon USA ISHLT Voices returns with another podcast presented by exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part two of this series, experts take a deep dive into the role of lung function monitoring post-transplant for the detection of chronic lung transplant rejection, specifically BOS. Shambhu Aryal, MD Medical Director, Lung Transplant Program Director, Sarcoidosis Clinic Inova Health System Falls Church, VA USA Justin P. Rosenheck, DO Clinical Assistant Professor of Internal...
info_outline
The Future of Bronchiolitis Obliterans Syndrome, From Zambon USA
ISHLT Voices
Presented by Zambon USA The first episode of ISHLT Voices is now live! This podcast, presented by , explores bronchiolitis obliterans syndrome (BOS), one of the most common forms of chronic lung transplant rejection. Despite advances in surgical techniques, BOS remains the Achilles heel of lung transplants. In this podcast, experts address critical questions regarding diagnosis, management, and future approaches for BOS. Shambhu Aryal, MDMedical Director, Lung Transplant Program Director, Sarcoidosis Clinic Inova Health System Falls Church, VA USA Howard J. Huang, MDChief, Section of Lung...
info_outlineIn this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear transplant cardiologists explore the evolving landscape of post-heart transplant care, zeroing in on the transformative shift from traditional, invasive biopsies to cutting-edge noninvasive molecular diagnostics—particularly cell-free DNA technologies.
Brent Lampert, DO
Medical Director, Transplant Cardiologist
The Ohio State University Wexner Medical Center
Columbus, OH USA
Ajith P. Nair, MD, FACC, FAHA
Associate Professor, Medicine—Cardiology
Texas Heart Institute at Baylor College of Medicine
Houston, TX USA
Drs. Lampert and Nair discuss the clinical promise of tools like Natera’s Prospera Heart with Donor Quantity Score (DQS), which not only offer heightened accuracy and earlier detection of graft injury and rejection, but also may empower clinicians to strike a vital balance: preventing rejection without over-immunosuppression.
Real-world insights, compelling case examples, and candid discussions about the challenges of biopsy-based monitoring—and how new technology is reshaping decisions, outcomes, and patient peace of mind—make this a must-listen for anyone intrigued by the future of transplantation medicine.
The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.
This episode was created for ISHLT Voices and sponsored by Natera.
